Pathway Genomics has launched its BreastTrue High Risk Panel, a next-generation sequencing-based assay with deletion/duplication analysis to detect mutations in seven high-risk cancer susceptibility genes — BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11, and TP53. The test can analyze DNA from either blood or saliva. In addition, it has now added the option for customers that test negative using its BRCATrue and BRCATrue Ashkenazi Jewish panels to reflex to the BreastTrue panel.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.